Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Dr. Ingrid Delaet will join the company’s executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr Ingrid Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021.

“Ingrid’s deep experience in regulatory affairs will be invaluable to Neurocrine as we work to advance our pipeline in our quest to relieve suffering for people with great needs, but few options,” said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “We are thrilled Ingrid is joining the management team to help lead our efforts to discover and develop life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.”

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016. Between 1997 and 2016, she held various positions of increasing responsibility at Bristol-Myers Squibb in the United States, first in Clinical Research and Development and then in Global Regulatory Affairs, where she served as Therapeutic Area Lead for Immunology. Dr. Delaet started her career in the pharmaceutical industry in Belgium, where she held positions in clinical research at CellPro and Wyeth-Ayerst Research. She received her Ph.D. in Immunology and her M. Sc. in Pharmaceutical Sciences from The Free University of Brussels, Belgium.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine